Turn Therapeutics Updates Investors on GX-03 Pipeline and Q1 2027 Atopic Dermatitis Readout
Turn Therapeutics (TTRX) updated investors on its GX-03 pipeline, including a Phase 2 trial for atopic dermatitis with results expected in Q1 2027, a Phase 2a trial for hidradenitis suppurativa planned for Q1 2027, and a Phase 3-ready onychomycosis treatment. The company reported $10.4M in cash as of September 30, 2026, with a runway into Q3 2027, and holds 17 issued patents.
